TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03419208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIN-HAND Program
Description: The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
Study: NCT03393104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise
Description: Activation of specific muscles of the lumbopelvic region responsible for providing stability or control of posture and movement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise
Description: Activation of specific muscles of the lumbopelvic region responsible for providing stability or control of posture and movement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Education aiming to change unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Education aiming to change unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
Study: NCT01466088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Subjects taking donepezil will take 1-2 capsules of 5 mg donepezil and a placebo for AZD3480 (to maintain blind) orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
Study: NCT03761966

Intervention type: OTHER
Intervention: Pregnant women
Study: NCT03908424

Intervention type: OTHER
Intervention: Epidural Blood patch.
Description: An epidural blood patch is a surgical procedure that uses autologous blood in order to close one or many holes in the dura mater of the spinal cord, usually as a result of a previous lumbar puncture. A small amount of the patient's blood is injected into the epidural space near the site of the original puncture; the resulting blood clot then patches the meningeal leak. An epidural needle is inserted into the epidural space at the site of the cerebrospinal fluid leak and blood is injected. The clotting factors of the blood close the hole in the dura.
Study: NCT02741154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRh a
Description: antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRh a
Description: antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Description: 10.000 IU HCG injection when at least three follicles reach 17mm in diameter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG
Description: 10.000 IU HCG injection when at least three follicles reach 17mm in diameter
Study: NCT03668431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be taken twice a day for 28 consecutive days~.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be taken once a day for 28 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 will be administered IV every 28 days
Study: NCT02277431

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic dietary supplement (Trenev Trio®)
Description: Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am \& pm) offering a total daily serving of:~* Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units \[CFU\])~* Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~* Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02400476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colestipol
Description: 2 g twice daily with or without food for one 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colestipol
Description: 2 g twice daily with or without food for one 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 9 mg extended release tablets once daily with or without food for 28 days
Study: NCT00965016

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermia
Description: Core temperature --\> 34.9℃ within 30 min --\> 33.5℃ within 120min --\> 33℃for 24 H Decrease temperature in 0.9℃/hour

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermia
Description: Core temperature --\> 34.9℃ within 30 min --\> 33.5℃ within 120min --\> 33℃for 24 H Decrease temperature in 0.9℃/hour

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: hypothermia
Description: Core temperature --\> 34.9℃ within 30 min --\> 33.5℃ within 120min --\> 33℃for 24 H Decrease temperature in 0.9℃/hour
Study: NCT03536182

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Ion Radiation Therapy (CIRT)
Description: Patient will receive CIRT daily, 4 days a week for a total of 12 fractions/treatments plus concurrent chemotherapy (gemcitabine) weekly for 3 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic. Within 6 weeks of completing radiotherapy, patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Patient will receive IMRT daily, 5 days a week for a total of 28 fractions/treatments plus concurrent chemotherapy (gemcitabine or capecitabine) weekly for 5 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic,within 6 weeks of completing radiotherapy,patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
Study: NCT03928535

Intervention type: DEVICE
Group type: OTHER
Intervention: High-FlowNasal Cannula
Description: High-flowoxygenwas applied immediately after extubation through specific nasal cannula. Flow was initially set at 10 L/min and titrated upwards in 5-L/min steps until patients experienced discomfort.Temperature was initially set to 37°C, unless reported too hot by patients, and FIO2 was regularly adjusted to the target peripheral capillary oxygen saturation (SPO2) of greater than 92%. After 24 hours, high-flow was stopped and, if necessary, patients received conventional oxygen therapy.

Intervention type: DEVICE
Group type: OTHER
Intervention: Noninvasive Ventilation
Description: Full face mask NIV was continuously delivered immediately after extubation for a scheduled period of 24 hours after extubation. Afterward, NIV was withdrawn and oxygen was administered by Venturi mask.Both PEEP and inspiratory pressure supportwere adjusted to target a respiratory rate of 25/min and adequate gas exchange (arterial oxygen saturation \[SaO2\] 92%, with pH of 7.35). The FIO2 was adjusted to maintain SPO2 at less than 92%. Sedatives to increase tolerance to NIV were not allowed.
Study: NCT02693756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks.
Study: NCT01413815

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: 3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
Study: NCT01242462

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pressure Controlled SIMV
Description: Initial ventilatory settings per clinical physician's discretion-tcCO2 \& Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
Study: NCT02100826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Administered orally.
Study: NCT01939145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prontosan
Description: Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
Study: NCT03429088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing telephone counseling
Study: NCT04557488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Each session will follow a similar structure with a hello song, musical activities, and a goodbye song. The musical activities will vary in each session and will be mixed in later sessions to revisit and practice social skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral-based social skill training
Description: Each intervention session will follow a standard structure of opening greetings, social activities according to the theme of the session, and a closing activity. The activities and games will vary in each session and will be mixed in later session to revisit and practice social skills.
Study: NCT02886897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-CIK and anti-PD-1 antibody
Description: Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
Study: NCT00807430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grindcare (Active)
Description: Active treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Grindcare (Placebo - the device is not activated)
Description: Placebo treatment
Study: NCT01003223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer algorithm management of hyperphosphatemia
Description: The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
Study: NCT02692573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positioning
Description: prone positioning for the initial 5 minutes of life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positioning
Description: supine positioning for the initial 5 minutes of life
Study: NCT05105724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP was prepared using double centrifugation of the patient's autologous whole blood, and 400 µL of PRP was injected via vaginal puncture into the ovarian parenchyma.
Study: NCT02990806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-071
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-071
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remicade
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remicade
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remicade
Description: IV infusion.
Study: NCT02457819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
Study: NCT01914172

Intervention type: OTHER
Intervention: online questionairres
Description: see group descriptions

Intervention type: OTHER
Intervention: online questionairres
Description: see group descriptions
Study: NCT03088878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
Description: Participants will receive escalating doses of cirmtuzumab (2-16 mg/kg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily, starting at week 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab (300mg) plus Ibrutinib
Description: Participants will receive cirmtuzumab (300 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab (600 mg) plus ibrutinib
Description: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab (RDR) plus ibrutinib
Description: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab plus ibrutinib
Description: Arm A: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
Study: NCT02460484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Cord Blood Infusion
Description: Intravenous infusion
Study: NCT01949740

Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03088878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib alone
Description: Arm B: Participants will receive ibrutinib (420 mg) orally once daily
Study: NCT01242462

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pressure Controlled SIMV
Description: Initial ventilatory settings per clinical physician's discretion-tcCO2 \& Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mid-frequency Ventilation
Description: Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is \>/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH \>/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mid-frequency Ventilation
Description: Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is \>/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH \>/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
Study: NCT04528732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (G-CBT)
Description: G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Family Group (MFG)
Description: MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
Study: NCT02674451

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
Study: NCT01099891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhEGF
Description: rhEGF 50 μg/ml, spray type, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Spray type, Twice a day
Study: NCT01215019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: 20% Mannitol, 1-5 doses as needed to control ICP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl
Description: 3% sodium chloride injection, 1-5 doses, as needed to control ICP